Levacetylmethadol

Levacetylmethadol

Clinical data
Routes of administration	Oral
ATC code	N07BC03 (WHO)
Legal status
Legal status	CA: Schedule I US: Schedule II
Pharmacokinetic data
Protein binding	~80%
Metabolism	CYP3A4
Elimination half-life	2.6 days
Identifiers
IUPAC name (3S,6S)-(6-dimethylamino-4,4-diphenyl-heptan-3-yl) acetate
CAS Number	1477-40-3 Y 43033-72-3 (hydrochloride)
PubChem CID	15130
DrugBank	15130 N
ChemSpider	14401 N
UNII	R3B637Y991
KEGG	D04716 Y
ChEMBL	ChEMBL1514 N
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C23H31NO2
Molar mass	353.498 g/mol
3D model (JSmol)	Interactive image
SMILES CC[C@@H](C(C[C@H](C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)OC(=O)C
InChI InChI=1S/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m0/s1 N Key:XBMIVRRWGCYBTQ-AVRDEDQJSA-N N
NY (what is this?)  (verify)

WikiDoc Resources for Levacetylmethadol
Articles
Most recent articles on Levacetylmethadol Most cited articles on Levacetylmethadol Review articles on Levacetylmethadol Articles on Levacetylmethadol in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Levacetylmethadol Images of Levacetylmethadol Photos of Levacetylmethadol Podcasts & MP3s on Levacetylmethadol Videos on Levacetylmethadol
Evidence Based Medicine
Cochrane Collaboration on Levacetylmethadol Bandolier on Levacetylmethadol TRIP on Levacetylmethadol
Clinical Trials
Ongoing Trials on Levacetylmethadol at Clinical Trials.gov Trial results on Levacetylmethadol Clinical Trials on Levacetylmethadol at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Levacetylmethadol NICE Guidance on Levacetylmethadol NHS PRODIGY Guidance FDA on Levacetylmethadol CDC on Levacetylmethadol
Books
Books on Levacetylmethadol
News
Levacetylmethadol in the news Be alerted to news on Levacetylmethadol News trends on Levacetylmethadol
Commentary
Blogs on Levacetylmethadol
Definitions
Definitions of Levacetylmethadol
Patient Resources / Community
Patient resources on Levacetylmethadol Discussion groups on Levacetylmethadol Patient Handouts on Levacetylmethadol Directions to Hospitals Treating Levacetylmethadol Risk calculators and risk factors for Levacetylmethadol
Healthcare Provider Resources
Symptoms of Levacetylmethadol Causes & Risk Factors for Levacetylmethadol Diagnostic studies for Levacetylmethadol Treatment of Levacetylmethadol
Continuing Medical Education (CME)
CME Programs on Levacetylmethadol
International
Levacetylmethadol en Espanol Levacetylmethadol en Francais
Business
Levacetylmethadol in the Marketplace Patents on Levacetylmethadol
Experimental / Informatics
List of terms related to Levacetylmethadol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Levacetylmethadol (INN), levomethadyl acetate (USAN), OrLAAM (trade name) or levo-α-acetylmethadol (LAAM) is a synthetic opioid similar in structure to methadone. It has a long duration of action due to its active metabolites. It was approved in 1993 by the U.S. Food and Drug Administration for use in the treatment of opioid dependence. In 2001, Orlaam was removed from the European market due to reports of life-threatening ventricular rhythm disorders. In 2003, Roxane Laboratories, Inc. discontinued Orlaam in the US.

Indications

LAAM is indicated as a second-line treatment for the treatment and management of opioid dependence if patients fail to respond to drugs like methadone or buprenorphine. Before August 1993, LAAM was classified as a schedule I drug in the United States. LAAM is not approved for use in Australia and Canada. At present, it is a Schedule II Narcotic controlled substance in the United States with a DEA ACSCN of 9648 and a national aggregate annual manufacturing quota of 4 grammes as of 2013.

Chemistry and pharmacology

Levacetylmethadyl acts as a mu-opioid receptor agonist. It also acts as a potent, noncompetitive α₃β₄ neuronal nicotinic acetylcholine receptor antagonist.

Levomethadyl acetate is the levo isomer of α-methadyl acetate. The dextro isomer, alphacetylmethadol, is more potent but shorter acting. The levo isomer is also less toxic with an Template:LD50 in mice of 110 mg/kg s.c. and 172.8 mg/kg orally as opposed to Template:LD50s of 61 mg/kg s.c. and 118.3 mg/kg orally for dl-α-methadyl acetate. It has a melting point of 215 °C and a molecular weight of 353.50. β-methadyl acetate also exists, however it is more toxic and less active than α-methadyl acetate and has no current medical use.

Levomethadyl acetate undergoes extensive first-pass metabolism to the active demethylated metabolite nor-LAAM, which is further demethylated to a second active metabolite, dinor-LAAM. These metabolites are more potent than the parent drug.

Dosing

LAAM is used as an oral solution of levomethadyl acetate hydrochloride at a concentration of 10 mg/mL in bottles of 120 and 500 mL under the brand name Orlaam. The first dose of LAAM for patients who have not started treatment with methadone is 20–40 mg. The first dose for patients who have been receiving methadone will be a little higher than the amount of methadone that was being taken every day, but not more than 120 mg. Afterwards, the dosage may be adjusted as needed. Unlike methadone, which requires daily administration, LAAM is administered two to three times a week.

See also

• Alphacetylmethadol
• Acetylmethadol
• Levomethadone

External links

• LAAM Drug Information
• RxList Monograph for Orlaam
• DrugBank: Levomethadyl Acetate
• http://cat.inist.fr/?aModele=afficheN&cpsidt=2706063
• http://cat.inist.fr/?aModele=afficheN&cpsidt=2390242

Template:Antiaddictives